Panitumumab Beats Bevacizumab in Left-Sided mCRC
The first trial comparing panitumumab or bevacizumab plus standard chemotherapy has shown that the former significantly improves survival in left-sided Ras wild type metastatic colorectal cancer.
Medscape Medical News
source https://www.medscape.com/viewarticle/975064?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/975064?src=rss
Comments
Post a Comment